Pelthos Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | $-43.3M | $-8.0M | $-7.4M | $-2.5M |
| Depreciation & Amortization | — | — | — | — |
| Depreciation | $729.0K | $0 | — | — |
| Amortization | $1.6M | $0 | — | — |
| Stock-Based Compensation | $5.5M | $1.8M | $1.7M | $110.1K |
| Net Cash from Operating Activities | $-22.6M | $-5.8M | $-981.0K | $-1.6M |
| Investing Activities | ||||
| Capital Expenditures | $99.0K | $0 | — | — |
| Business Acquisitions | — | — | — | — |
| Net Cash from Investing Activities | $-5.2M | $0 | — | — |
| Financing Activities | ||||
| Dividends Paid | — | — | — | — |
| Stock Repurchases | $0 | $75.0K | — | — |
| Net Cash from Financing Activities | $45.3M | $6.2M | $1.0M | $1.6M |
| Net Change in Cash | — | — | — | — |
| Free Cash Flow | $-22.7M | $-5.8M | — | — |